Mast Therapeutics, Inc. (MSTX)

[Bx3]

Lux, it is so good to be able to continue to return to these four documents you presented here. Though highly technical in format, each addresses a different exploratory of the application of MST 188 to human blood. These appear to agree and justify certain enhancements with SCD, (and refer to The EPIC Study, ph.3 ongoing. ) But , because they address cell aggregations, adhesions, sickle shaped cell chemical release, cell destruction, viscosity, and surfactant qualities, the generalized overflow , to failing cardiac vessels/ blood / repair (and the same considerations with neural sroke ) appear obvious, IMO. The near term reporting of these current findings in Orlando , are in keeping with the MSTX product pipeline introduction ,nationally and internationally.

These seeming PPS manipulations are definitely advantageous to some, for whatever reasons, current. But , as my strategy does not include short term trading, my investment displays no loss. I continue to regard this circumstance as , of a lesser , longterm significance. If thats a pump statement, so be it. Contented and maintaining focus on end results of three studies ongoing.GLTA. All stated IMO.